High-fat diet-induced adipose tissue expansion occurs prior to insulin resistance in C57BL/6J mice.
High-fat diet
Metabolic dysfunction
Metabolic inflammation
Obesity
Journal
Chronic diseases and translational medicine
ISSN: 2589-0514
Titre abrégé: Chronic Dis Transl Med
Pays: United States
ID NLM: 101679934
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
09
11
2019
entrez:
5
9
2020
pubmed:
5
9
2020
medline:
5
9
2020
Statut:
epublish
Résumé
To date, there is only scare evidence characterizing the temporal features and progression of metabolic dysfunction in high-fat diet (HFD)-fed obese mice. Hence, its specific pathogenesis remains unclear. Sixty 6-week-old male C57BL/6J mice were randomly divided into HFD and control diet (CD) groups and sacrificed at 1, 5, 9, 13, 17, and 21 weeks, respectively. At weekly intervals, intraperitoneal glucose tolerance testing (IPGTT) and intraperitoneal insulin tolerance testing (IPITT) were performed in both groups. A detailed time course in HFD-fed mice was investigated by evaluating the initiation of glucose homeostasis impairment, dyslipidemia, systemic insulin sensitivity, monocyte chemoattractant protein-1 (MCP-1) levels, epididymal white adipose tissue (eWAT) expansion, macrophage content changes, pro-inflammatory (M1)/anti-inflammatory (M2) macrophage imbalance, lipid accumulation in the liver, and β-cell morphometry in the pancreas. In the HFD group, progressive weight gain and impairments in glucose metabolism (elevated fasting blood glucose and area under the curve (AUC) of IPGTT) were observed from the 3rd week, and a significantly elevated AUC of IPITT was first detected after week 7 of HFD feeding. As for dyslipidemia, after 9 weeks of feeding, the low-density lipoprotein cholesterol level and total cholesterol level in HFD group were significantly higher than those in the CD group (all The eWAT expansion was detected early in HFD-induced obese mice, which occurred prior to obvious insulin resistance.
Sections du résumé
BACKGROUND
BACKGROUND
To date, there is only scare evidence characterizing the temporal features and progression of metabolic dysfunction in high-fat diet (HFD)-fed obese mice. Hence, its specific pathogenesis remains unclear.
METHODS
METHODS
Sixty 6-week-old male C57BL/6J mice were randomly divided into HFD and control diet (CD) groups and sacrificed at 1, 5, 9, 13, 17, and 21 weeks, respectively. At weekly intervals, intraperitoneal glucose tolerance testing (IPGTT) and intraperitoneal insulin tolerance testing (IPITT) were performed in both groups. A detailed time course in HFD-fed mice was investigated by evaluating the initiation of glucose homeostasis impairment, dyslipidemia, systemic insulin sensitivity, monocyte chemoattractant protein-1 (MCP-1) levels, epididymal white adipose tissue (eWAT) expansion, macrophage content changes, pro-inflammatory (M1)/anti-inflammatory (M2) macrophage imbalance, lipid accumulation in the liver, and β-cell morphometry in the pancreas.
RESULTS
RESULTS
In the HFD group, progressive weight gain and impairments in glucose metabolism (elevated fasting blood glucose and area under the curve (AUC) of IPGTT) were observed from the 3rd week, and a significantly elevated AUC of IPITT was first detected after week 7 of HFD feeding. As for dyslipidemia, after 9 weeks of feeding, the low-density lipoprotein cholesterol level and total cholesterol level in HFD group were significantly higher than those in the CD group (all
CONCLUSION
CONCLUSIONS
The eWAT expansion was detected early in HFD-induced obese mice, which occurred prior to obvious insulin resistance.
Identifiants
pubmed: 32885155
doi: 10.1016/j.cdtm.2020.06.003
pii: S2095-882X(20)30062-1
pmc: PMC7451745
doi:
Types de publication
Journal Article
Langues
eng
Pagination
198-207Informations de copyright
© 2020 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
Déclaration de conflit d'intérêts
None.
Références
Nature. 2006 Dec 14;444(7121):860-7
pubmed: 17167474
Diabetes. 2009 Jan;58(1):104-15
pubmed: 18835938
J Endocrinol. 2017 Apr;233(1):53-64
pubmed: 28138002
Int J Mol Sci. 2014 Apr 11;15(4):6184-223
pubmed: 24733068
Biomed Pharmacother. 2019 Jun;114:108781
pubmed: 30903919
Diabetes Care. 2005 Nov;28(11):2745-9
pubmed: 16249550
J Clin Invest. 2016 Jan;126(1):12-22
pubmed: 26727229
Diabetes. 2005 Aug;54(8):2294-304
pubmed: 16046294
J Biol Chem. 2017 Jul 28;292(30):12449-12459
pubmed: 28487366
Nature. 2017 Feb 8;542(7640):177-185
pubmed: 28179656
Prog Cardiovasc Dis. 2016 Sep - Oct;59(2):172-177
pubmed: 27497505
Diabetes. 2011 Oct;60(10):2474-83
pubmed: 21911747
J Clin Invest. 2011 Jun;121(6):2111-7
pubmed: 21633179
Nutrients. 2013 May 21;5(5):1672-705
pubmed: 23698162
J Clin Invest. 2017 Jan 3;127(1):1-4
pubmed: 28045402
Nutr Metab (Lond). 2016 Oct 4;13:65
pubmed: 27708685
Diabetes. 2004 Dec;53 Suppl 3:S215-9
pubmed: 15561913
Cell Biosci. 2017 Oct 25;7:54
pubmed: 29090088
Biochem Pharmacol. 2016 Jan 1;99:1-10
pubmed: 26432954
Nutrients. 2017 Aug 22;9(8):
pubmed: 28829397
Diabetologia. 2001 Mar;44(3):312-9
pubmed: 11317662
J Lipid Res. 2008 Jul;49(7):1562-8
pubmed: 18390487
N Engl J Med. 2007 Jan 18;356(3):213-5
pubmed: 17229948
J Vis Exp. 2018 Jan 7;(131):
pubmed: 29364280
Aging (Albany NY). 2015 Apr;7(4):256-68
pubmed: 25979814
Eur J Nutr. 2018 Feb;57(1):279-295
pubmed: 27757592
Cell Cycle. 2014;13(2):184-90
pubmed: 24394850